Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02045095 · ClinicalTrials.gov registry record · Phase 1
A Dose Escalation Study of MLN7243 (TAK-243) in Adult Participants With Advanced Solid Tumors
A Phase 1 study, sponsored by Millennium Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
NCT02045095 is a Phase 1 study that was terminated before completion, run by Millennium Pharmaceuticals. The registered enrollment target is 29 participants.
The verdict
NCT02045095, a Phase 1 study, was terminated before completion, sponsored by Millennium Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate safety and tolerability (establish maximum tolerated dose \[MTD\], inform the recommended phase 2 dose \[RP2D\], and identify the dose-limiting toxicities \[DLTs\]) of MLN7243.
Interventions
- DRUG MLN7243
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2014-01-31 |
| Est. Completion | 2016-11-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02045095
The ClinicalTrials.gov registry entry for NCT02045095 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Millennium Pharmaceuticals, which has 135 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MLN7243 is the first listed.
NCT02045095 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02045095 about?
NCT02045095 is a clinical study titled "A Dose Escalation Study of MLN7243 (TAK-243) in Adult Participants With Advanced Solid Tumors". The purpose of this study is to evaluate safety and tolerability (establish maximum tolerated dose \[MTD\], inform the recommended phase 2 dose \[RP2D\], and identify the dose-limiting toxicities \[DLTs\]) of MLN7243.
What is the current status of trial NCT02045095?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2014-01-31. Estimated completion is 2016-11-09.
What interventions are being tested in trial NCT02045095?
The interventions under investigation include: MLN7243 (DRUG).
Who is sponsoring clinical trial NCT02045095?
This trial is sponsored by Millennium Pharmaceuticals, which has 135 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.